ReviewFrontiers in immunology2020
Targeting the PD-1/PD-L1 Axis in Human Vitiligo.
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Regulatory T Cell Dysregulation in Vitiligo: A Meta-Analysis and Systematic Review of Immune Mechanisms and Therapeutic Perspectives.International journal of dermatology · 2025Pooled it
- Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.PloS one · 2021Pooled it
- Ritlecitinib, a JAK3/TEC family kinase inhibitor, stabilizes active lesions and repigments stable lesions in vitiligo.Archives of dermatological research · 2024Trial
- UV irradiation drives lineage-specific MITF-mediated transcription of PD-L1 to confer immune tolerance to UV-mutated melanocytes.Immunity · 2026Article
- Repigmentation Competence in Vitiligo: Integrating Immune, Regulatory, Regenerative, and Microenvironmental Axes.Journal of personalized medicine · 2026Review
- Immune control of functional memory CD8 T cells in normal-appearing vitiligo skin.Science advances · 2025Article
- Implication of Immunobiological Function of Melanocytes in Dermatology.Clinical reviews in allergy & immunology · 2025Review
- Targeted therapies induced depigmentation: a review.Frontiers in immunology · 2025Review
- Assessment of PD-1 and PD-L1 tissue expression levels in lichen planus patients: a case-control study.Archives of dermatological research · 2024Article
- Identification of Hub Genes in Comorbidity of Psoriasis and Vitiligo Using Bioinformatics Analysis.Clinical, cosmetic and investigational dermatology · 2024Article
- Article
- CMTM6: increased circulating level and up-regulated expression in labial salivary glands in patients with primary Sjogren's syndrome.Clinical and experimental immunology · 2022Article
- Hair Graying Regulators Beyond Hair Follicle.Frontiers in physiology · 2022Article
- Canities Subita after Extreme Trauma Showing Positive Staining for Anti-PD-L1 Antibodies: A New Clue into Etiopathogenesis?Skin appendage disorders · 2022Article
- Translational Research in Vitiligo.Frontiers in immunology · 2021Review
- Recent Advances in Management of Vitiligo.Indian journal of dermatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoreactive CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.